10月15日，Moderna盘中下跌3.12%，报231.099美元/股，成交额7.17亿美元。
消息面上，市场此前持续交易个体化癌症疫苗intismeran autogene商业化预期升温，叠加板块回暖推动股价走强；但在前一时段盘中上涨3.05%后，短线资金获利回吐压力再度显现。
此前公司与默沙东、Tempus扩大合作，以支持该疗法潜在商业化落地，同时美国国立卫生研究院参与加速癌症疫苗开发的公私合作计划，持续强化mRNA肿瘤疫苗赛道预期。不过在股价快速拉升后，增量催化的边际影响有所减弱。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.